The FDA recently approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis. Zinbryta is a long-acting subcutaneous injection that is administered once a month. Zinbryta has shown efficacy in two large clinical trials, one of which compared this drug to Avonex. There are additional safety concerns with this medication, however, including possible damage to the liver. Patients on Zinbryta will have to perform blood tests to monitor liver function... more


The IMSMP is starting a new group for patients of the Center, who want to socialize and support one another yet may have difficulty traveling to the city. The group meets over the phone, once a month on Wednesdays. There are also openings to join the support group for newly diagnosed patients. For more information on either of these groups, please contact the Social Work Department at (212) 265-8070.


In observance of Memorial Day, the IMSMP will close today at 2:30pm and re-open on Tuesday, May 31st. For any emergency, a neurologist will be on-call and may be reached at (212) 265-8070. We thank women and men everywhere for their service to our country and we wish you a safe & healthy holiday weekend.


The spring issue of the IMSMP newsletter, Healing MS is here!


Do you suffer from seasonal allergies? If so, contact the nurse's phone line at the IMSMP to discuss which allergy medication is right for you. Call (212) 265-8070.


Last week during the American Academy of Neurology (AAN) Annual Meeting, Neurology Advisor sat down with Dr. Saud A. Sadiq to discuss the results of Tisch MSRCNY's Phase I Stem Cell Trial for MS. Please visit the link below to read: Stem Cell-Derived Therapy Shows Promise in Progressive Multiple Sclerosis. more



Because you deserve only the best in MS healthcare. Experience the difference.

Newsletter Sign Up

Join our mailing list today!  Receive the latest information and updates happening in MS research, treatment and care including, Healing MS, the IMSMP newsletter.

* We don’t share your information with anyone.